Supernus Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
778
- Stock Symbol
-
SUPN
- Investments
-
6
- Share Price
-
$29.72
- (As of Friday Closing)
Supernus General Information
Description
Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The company's commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Contact Information
Website
www.supernus.comCorporate Office
- 9715 Key West Avenue
- Rockville, MD 20850
- United States
Corporate Office
- 9715 Key West Avenue
- Rockville, MD 20850
- United States
Supernus Stock Performance
As of 13-Nov-2026, Supernus’s stock price is $29.72. Its current market cap is $6.17B with 208M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $29.72 | $29.20 | $25.92 - $59.68 | $6.17B | 208M | 1.38M | -$0.76 |
Supernus Financials Summary
As of 30-Sep-2026, Supernus has a trailing 12-month revenue of $865M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,174,070 | 2,610,818 | 1,631,672 | 1,423,207 |
| Revenue | 865,106 | 718,952 | 661,817 | 607,521 |
| EBITDA | 51,469 | 29,317 | 162,080 | 79,631 |
| Net Income | (43,856) | (38,550) | 73,865 | 1,316 |
| Total Assets | 1,397,690 | 1,452,648 | 1,368,073 | 1,277,673 |
| Total Debt | 36,197 | 40,977 | 34,271 | 41,527 |
Supernus Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Supernus Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Supernus Comparisons
Industry
Financing
Details
Supernus Competitors (108)
One of Supernus’s 108 competitors is Mesoblast, a Corporation company based in Melbourne, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mesoblast | Corporation | Melbourne, Australia | ||||
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Marinus Pharmaceuticals | Private Equity-Backed | Radnor, PA | ||||
| Damora Therapeutics ( Drug Discovery) | Formerly VC-backed | Waltham, MA | ||||
| Gilead | Formerly VC-backed | Foster City, CA |
Supernus Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Supernus Patents
Supernus Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250108038-A1 | Substituted derivatives of isoindoles and uses thereof | Pending | 29-Sep-2023 | ||
| AU-2024352930-A1 | Substituted derivatives of isoindoles for use in the treatment of central nervous system disorders | Pending | 29-Sep-2023 | ||
| EP-4784120-A1 | Substituted derivatives of isoindoles for use in the treatment of central nervous system disorders | Pending | 29-Sep-2023 | ||
| WO-2025072583-A1 | Substituted derivatives of isoindoles for use in the treatment of central nervous system disorders | Inactive | 29-Sep-2023 | ||
| AU-2024301265-A1 | Substituted derivatives of isoindoles | Active | 26-Jul-2023 | C07D487/04 |
Supernus Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Supernus Investments & Acquisitions (6)
Supernus’s most recent deal was a Merger/Acquisition with Indivior for . The deal was made on 02-Nov-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Indivior | 02-Nov-2026 | Merger/Acquisition | Drug Discovery | ||
| SAGE Therapeutics | 31-Jul-2025 | Merger/Acquisition | Drug Discovery | ||
| Adamas Pharmaceuticals | 24-Nov-2021 | Merger/Acquisition | Drug Discovery | ||
| US WorldMeds (CNS Portfolio) | 09-Jun-2020 | Corporate Asset Purchase | Buildings and Property | ||
| Navitor Pharmaceuticals | 06-May-2020 | Later Stage VC | Drug Discovery |
Supernus ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
31.92 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Supernus Exits (1)
Supernus’s most recent exit was on 06-May-2020 from Navitor Pharmaceuticals. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Navitor Pharmaceuticals | 06-May-2020 | Completed |
|
Supernus Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Indivior | North Chesterfield, VA | 2014 |
Supernus FAQs
-
When was Supernus founded?
Supernus was founded in 2005.
-
Where is Supernus headquartered?
Supernus is headquartered in Rockville, MD.
-
What is the size of Supernus?
Supernus has 778 total employees.
-
What industry is Supernus in?
Supernus’s primary industry is Drug Discovery.
-
Is Supernus a private or public company?
Supernus is a Public company.
-
What is Supernus’s stock symbol?
The ticker symbol for Supernus is SUPN.
-
What is the current stock price of Supernus?
As of 13-Nov-2026 the stock price of Supernus is $29.72.
-
What is the current market cap of Supernus?
The current market capitalization of Supernus is $6.17B.
-
What is Supernus’s current revenue?
The trailing twelve month revenue for Supernus is $865M.
-
Who are Supernus’s competitors?
Mesoblast, ACADIA Pharmaceuticals, Marinus Pharmaceuticals, Damora Therapeutics ( Drug Discovery), and Gilead are some of the 108 competitors of Supernus.
-
What is Supernus’s annual earnings per share (EPS)?
Supernus’s EPS for 12 months was -$0.76.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
